Mechanisms and management of the heart in myotonic dystrophy

Heart

Volumn 97, Issue 13, 2011, Pages 1094-1100

  McNally, Elizabeth M ^a   Sparano, Dina ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METHYLPHENIDATE; MEXILETINE; MODAFINIL; PROTEIN KINASE C INHIBITOR; WARFARIN;

ARTIFICIAL HEART PACEMAKER; AUTOSOMAL DOMINANT INHERITANCE; CARDIOMYOPATHY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DEFIBRILLATION; DISEASE CLASSIFICATION; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FATIGUE; GENETIC ANALYSIS; GENETIC COUNSELING; HEART ARRHYTHMIA; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HIGH RISK POPULATION; HOLTER MONITORING; HUMAN; MOLECULAR PATHOLOGY; MORTALITY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOTONIC DYSTROPHY; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; SOMNOLENCE; THROMBOSIS; TISSUE DOPPLER IMAGING; TRINUCLEOTIDE REPEAT;

ALGORITHMS; CARDIOVASCULAR AGENTS; CHROMOSOME ABERRATIONS; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; YOUNG ADULT;

EID: 79958043227     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.214197     Document Type: Review

References (23)

1. Mathieu J, Allard P, Potvin L, et al. 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology 1999;52:1658-62. (Pubitemid 29220644)
2. Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008;358:2688-97. Large study of DM1 patients that describes risks for developing sudden cardiac death.
3. Pelargonio G, Dello Russo A, Sanna T, et al. Myotonic dystrophy and the heart. Heart 2002;88:665-70. Comprehensive review of DM1 and cardiac complications.
4. MacDonald JR, Hill JD, Tarnopolsky MA. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 2002;59:1876-80. (Pubitemid 36076558)
5. Antonini G, Giubilei F, Mammarella A, et al. Natural history of cardiac involvement in myotonic dystrophy: correlation with CTG repeats. Neurology 2000;55:1207-9.
6. Melacini P, Villanova C, Menegazzo E, et al. Correlation between cardiac involvement and CTG trinucleotide repeat length in myotonic dystrophy. J Am Coll Cardiol 1995;25:239-45.
7. Groh WJ, Lowe MR, Zipes DP. Severity of cardiac conduction involvement and arrhythmias in myotonic dystrophy type 1 correlates with age and CTG repeat length. J Cardiovasc Electrophysiol 2002;13:444-8. (Pubitemid 34494263)
8. Wahbi K, Meune C, Becane HM, et al. Left ventricular dysfunction and cardiac arrhythmias are frequent in type 2 myotonic dystrophy: a case control study. Neuromuscul Disord 2009;19:468-72. Describes cardiovascular complications with DM2.
9. Koshelev M, Sarma S, Price RE, et al. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet 2010;19:1066-75.
10. Wheeler TM, Sobczak K, Lueck JD, et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009;325:336-9. Animal model of DM1 shows the reversible nature of the cardiovascular complications.
11. Bassez G, Lazarus A, Desguerre I, et al. Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1. Neurology 2004;63:1939-41. Describes the pattern of arrhythmias in young patients with DM1 including exercise induced atrial arrhythmias.
12. Nguyen HH, Wolfe JT 3rd, Holmes DR Jr, et al. Pathology of the cardiac conduction system in myotonic dystrophy: a study of 12 cases. J Am Coll Cardiol 1988;11:662-71. (Pubitemid 18060228)
13. Merino JL, Carmona JR, Fernandez-Lozano I, et al. Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implications for catheter ablation. Circulation 1998;98:541-6. (Pubitemid 28371252)
14. Bhakta D, Lowe MR, Groh WJ. Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type I. Am Heart J 2004;147:224-7. (Pubitemid 38176820)
15. Morner S, Lindqvist P, Mellberg C, et al. Profound cardiac conduction delay predicts mortality in myotonic dystrophy type 1. J Intern Med 2010;268:59-65.
16. Dello Russo A, Mangiola F, Della Bella P, et al. Risk of arrhythmias in myotonic dystrophy: trial design of the RAMYD study. J Cardiovasc Med (Hagerstown) 2009;10:51-8.
17. Duboc D, Meune C, Pierre B, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007;154:596-602. Demonstrates the value of prophylactic treatment with ACE inhibitors in another form of muscular dystrophy, Duchenne muscular dystrophy.
18. Logigian EL, Martens WB, Moxley RT 4th, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010;74:1441-8. Describes the use of mexiletine in DM1 for the treatment of myotonia.
19. Heatwole CR, Eichinger KJ, Friedman DI, et al. Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1. Arch Neurol 2011;68:37-44.
20. Laurent V, Pellieux S, Corcia P, et al. Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices. Int J Cardiol 2010 Mar 11. [Epub ahead of print]. PMID:20227121.
21. Casella M, Dello Russo A, Pace M, et al. Heart rate turbulence as a noninvasive risk predictor of ventricular tachyarrhythmias in myotonic dystrophy type 1. J Cardiovasc Electrophysiol 2006;17:871-6. (Pubitemid 44079747)
22. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008;117:e350-408.
23. Wang GS, Kuyumcu-Martinez MN, Sarma S, et al. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest 2009;119:3797-806.